Unknown

Dataset Information

0

Incidence of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome and impact on patient outcome.


ABSTRACT:

Objectives and design

We used data from a randomized trial of HIV-tuberculosis co-infected patients in Mozambique to determine the incidence and predictors of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome (IRIS) occurring within 12 weeks of starting antiretroviral therapy, and to evaluate its association with patient outcome at 48 weeks.

Methods

HIV-tuberculosis co-infected and antiretroviral therapy-naïve adults with less than 250 CD4/mm3 were randomized to a nevirapine or efavirenz-based antiretroviral therapy initiated 4 to 6 weeks after starting tuberculosis treatment, and were then followed for 48 weeks. Tuberculosis cases were diagnosed using WHO guidelines, and tuberculosis-IRIS by case definitions of the International Network for the Study of HIV-associated IRIS.

Results

The 573 HIV-tuberculosis co-infected patients who initiated antiretroviral therapy had a median CD4 count of 92 cells/mm(3) and HIV-1 RNA of 5.6 log10 copies/mL. Mortality at week 48 was 6.1% (35/573). Fifty-three (9.2%) patients presented a tuberculosis-IRIS within 12 weeks of starting antiretroviral therapy. Being female and having a low CD4 count, high HIV-1 RNA load, low body mass index and smear-positive pulmonary tuberculosis were independently associated with tuberculosis-IRIS. After adjustment for baseline body mass index, CD4 count and hemoglobin, occurrence of tuberculosis-IRIS was independently associated with 48-week mortality (aOR 2.72 95%CI 1.14-6.54). Immunological and HIV-1 virological responses and tuberculosis treatment outcomes were not different between patients with and without tuberculosis-IRIS.

Conclusion

In this large prospective cohort, tuberculosis-IRIS occurrence within 12 weeks of starting antiretroviral therapy was independently associated with the mortality of HIV-tuberculosis co-infected patients at 48 weeks post antiretroviral therapy initiation.

SUBMITTER: Bonnet M 

PROVIDER: S-EPMC3867516 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature

altmetric image

Publications

Incidence of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome and impact on patient outcome.

Bonnet Maryline M   Baudin Elisabeth E   Jani Ilesh V IV   Nunes Elizabete E   Verhoustraten François F   Calmy Alexandra A   Bastos Rui R   Bhatt Nilesh B NB   Michon Christophe C  

PloS one 20131218 12


<h4>Objectives and design</h4>We used data from a randomized trial of HIV-tuberculosis co-infected patients in Mozambique to determine the incidence and predictors of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome (IRIS) occurring within 12 weeks of starting antiretroviral therapy, and to evaluate its association with patient outcome at 48 weeks.<h4>Methods</h4>HIV-tuberculosis co-infected and antiretroviral therapy-naïve adults with less than 250 CD4/mm3 were ra  ...[more]

Similar Datasets

| S-EPMC4319311 | biostudies-literature
| S-EPMC2940061 | biostudies-literature
2013-06-24 | E-GEOD-48237 | biostudies-arrayexpress
| S-EPMC6051466 | biostudies-literature
2019-01-29 | GSE108649 | GEO
| S-EPMC4772844 | biostudies-literature
| S-EPMC5359457 | biostudies-other
2013-06-24 | GSE48237 | GEO
| S-EPMC3443811 | biostudies-other
| S-EPMC4657750 | biostudies-literature